Unboosted atazanavir for treatment of HIV infection: Rationale and recommendations for use

Drugs

Volumn 72, Issue 9, 2012, Pages 1161-1173

  Focà, Emanuele ^a   Ripamonti, Diego ^b   Motta, Davide ^a   Torti, Carlo ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Antiretrovirals; Atazanavir; Dolutegravir; Efavirenz; HIV infections; Integrase inhibitors; Lamivudine; Nucleoside reverse transcriptase inhibitors; Paclitaxel; Peptide hydrolase inhibitors; Raltegravir; Repaglinide; Ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHADONE; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; VIRUS RNA;

ANTIDIARRHEAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; LIVER FAILURE; MIXED INFECTION; NONHUMAN; PREGNANT WOMAN; REVIEW; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; OLIGOPEPTIDES; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84862134392     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11631070-000000000-00000     Document Type: Review

References (59)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853-60 (Pubitemid 28135961)
2. van Heeswijk RP, Veldkamp A, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6 (4): 201-29 (Pubitemid 34174760)
3. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002; 36 (4): 702-6 (Pubitemid 34270289)
4. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001; 11 (2): 87-98 (Pubitemid 32172758)
5. Røge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med 2004; 5 (5): 344-51 (Pubitemid 39276332)
6. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160 (13): 2050-6 (Pubitemid 30437589)
7. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixeddose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS 2011; 25 (15): 1881-6
8. Bristol-Myers Squibb Company. Reyataz-(atazanavir sulfate) capsules:US prescribing information [online].Available from URL: http://packageinserts.bms. com/pi/pi-reyataz. pdf [Accessed 2012May 7]
9. European Medicines Agency. Reyataz: summary of product characteristics [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document- library/EPA-Produc-Information/human/000494/WC500056380.pdf [Accessed 2012 May 7]
10. McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 2009; 14 (1): 1-12
11. Nachega JB, Mugavero MJ, Zeier M, et al. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Pat Pref Adher 2011; 5: 357-67
12. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44 (11): 1484-92 (Pubitemid 46801594)
13. Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavirboosted atazanavir in HIV-infected patients. AIDS 2010; 24 (13): 2019-27
14. Ghosn J, Carosi G, Moreno S, et al. Unboosted atazanavirbased therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010; 15 (7): 993-1002
15. Giuntini R, Martinelli C, Ricci E, et al. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med 2010; 11 (1): 40-5
16. Santos JR, Moltó J, Llibre JM, et al. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavirsparing simplification strategy in routine clinical practice. HIV Clin Trials 2009; 10 (3): 129-34
17. Pavie J, Porcher R, Torti C, et al. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother 2011; 66 (10): 2372-8
18. Hocqueloux L, Le Moal G, De la Tribonnière X, et al. Maintenance therapy with unboosted atazanavir is comparable to boosted strategy in experienced patients, even with tenofovir: a multicentre propensity-adjusted cohort. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17-20; Rome
19. Soriano V, Garća-Gascó P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIVinfected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008; 61 (1): 200-5
20. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravirbased regimen versus continuation of a lopinavir-ritonavirbased regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375 (9712): 396-407
21. Carey D, Amin J, Boyd M, et al. Lipid profiles in HIVinfected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65 (9): 1878-88
22. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009; 37 (3): 244-9
23. Squires K, Young B, DeJesus E, et al. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC+ ATV/RTV in HIV-1 infected patients: final (144 weeks) results of the op. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17-20; Rome
24. Department of Health & Human Services. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents-a working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011 Oct 14 [online]. Available from URL: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 2012 May 7]
25. European AIDS Clinical Society (EACS). Guidelines. Version 6, Oct 2011 [online]. Available from URL: http://www.europeanaidsclinicalsociety.org/images/ stories/EACSPdf/eacsguidelines-v6-english.pdf [Accessed 2012 May 7]
26. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17 (18): 2603-14 (Pubitemid 38402338)
27. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36 (5): 1011-9 (Pubitemid 38989366)
28. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 2009; 69 (8): 1107-40
29. Malan DRN, Krantz E, David N, et al. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Ass Phys AIDS Care 2002; 9 (1): 34-42
30. Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis 2006; 6 (4): 215-25
31. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Op 2005; 21 (10): 1683-92 (Pubitemid 41505034)
32. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21 (18): 2409-15 (Pubitemid 350145172)
33. Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIVinfected pregnant women. HIV Med 2011; 12 (9): 570-9
34. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56 (5): 412-9
35. Eley T, Vandeloise E, Child M, et al. Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300mg once daily/ritonavir 100mg once daily+ ZDV/3TC during the third trimester in HIV+ women [abstract no. 624]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
36. FDA notifications. FDA approves new atazanavir labeling. AIDS Alert 2011; 26 (3): 33-4
37. Guaraldi G, Cocchi S, Motta A, et al. Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection 2009; 37 (3): 250-5
38. Regazzi M, Villani P, Gulminetti R, et al. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit 2011; 33 (3): 303-8
39. Kiser JJ, Burton JR, Anderson PL, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55 (5): 1620-8
40. Van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract no. 119]. 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27-Mar 2; Boston (MA)
41. Hulskotte E, Feng H, Van Zutven M, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir [abstract no. 771LB]. 19th Conference on Retroviruses and Opportunistic Infections; 2012 Mar 5-8; Seattle (WA)
42. Calcagno A, Bonora S, Tettoni MC, et al. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. J Acquir Immune Defic Syndr 2009; 52 (3): 431-2
43. Rodŕguez-Nó voa S, Morello J, Barreiro P, et al. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retrovir 2008; 24 (6): 821-5 (Pubitemid 351871672)
44. No authors listed. Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread)-and warning on Viagra, Cialis, and Levitra. AIDS Treat News 2004 Mar 26; (399): 5
45. Von Hentig N, Dauer B, Haberl A, et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 2007; 63 (10): 935-40 (Pubitemid 47387910)
46. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 2008; 52 (2): 631-7 (Pubitemid 351170838)
47. Stö hr W, Back D, Dunn D, et al. Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother 2010; 65 (1): 129-37
48. Fournier C, Higgins N, Thomas R, et al. Retrospective analysis of atazanavir therapeutic drug monitoring: is boosting with ritonavir necessary if atazanavir is used with tenofovir? [abstract no. P41] 12th International Workshop on Clinical Pharmacology of HIV Therapy; 2011 Apr 13-15; Miami (FL)
49. Cattaneo D, Ripamonti D, Baldelli S, et al. Exposurerelated effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit 2010; 32 (6): 782-6
50. Cordery DV, Hesse K, Amin J, et al. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther 2010; 15 (7): 1035-8
51. Carey D, Pett SL, Bloch M, et al. A randomized study of pharmacokinetics, efficacy and safety of two raltegravir plus atazanavir strategies in ART-treated adults. J Acquir Immune Def Syndr. Epub 2012 Mar 14
52. Kozal MJ, Lupo S, Dejesus E, et al. A nucleoside-and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clin Trials 2012; 13 (3): 119-30
53. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the nextgeneration HIV integrase inhibitor, S/GSK1349572. Brit J Clin Pharmacol 2011; 72 (1): 103-8
54. Haberl A, Moesch M, Nisius G, et al. Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a oncedaily observed therapy setting. Eur J Clin Pharmacol 2010; 66 (4): 375-81
55. Bertz R, Wang, Mahnke L, et al. Assessment of pharmacokinetic/ pharmacodynamic relationships through 48 weeks from a study in HIV+, ARV-naive subjects receiving ART regimens containing atazanavir 400 mg or atazanavir/ritonavir 300/100 mg once daily [abstract no. 565]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
56. Taburet A-M, Vincent I, Girard P-M, et al. Parmakokinetics of atazanavir administered once daily with or without ritonavir in HIV-infected patients: INDUMA study [abstract no. P32]. 10th International Workshop on Clinical Pharmacology of HIV Therapy; 2009 Apr 15-17; Amsterdam
57. Moltó J, Santos JR, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit 2007; 29 (5): 648-51 (Pubitemid 47494066)
58. Bonora S, Gonzalez de Requena D, D'Avolio A, et al. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Antivir Ther 2011; 16 (4): 499-504
59. Zhu L, Butterton J, Persson A, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther 2010; 15 (8): 1107-14